Navigation Links
ChemoCentryx Announces Pricing of Initial Public Offering
Date:2/8/2012

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the pricing of its initial public offering of 4,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by ChemoCentryx. In addition, the underwriters have a 30-day option to purchase up to an additional 675,000 shares of common stock from ChemoCentryx to cover over-allotments, if any.

Shares of ChemoCentryx's common stock will trade on the NASDAQ Global Select Market under the symbol "CCXI" beginning on February 8, 2012. The offering is expected to close on February 13, 2012, subject to customary closing conditions.

J.P. Morgan Securities LLC and Citigroup are acting as joint book-running managers of the offering, and Cowen and Company, LLC is acting as co-manager of the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 8, 2012. This offering is being made only by means of a prospectus, copies of which may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by phone at 866-803-9204, or from Citigroup, Attn: Prospectus Delivery Department, Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220 or by phone at 718-765-6732.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About ChemoCentryx 

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the c
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
2. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
3. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
4. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
5. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
9. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
10. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
11. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... About Balloon Kyphoplasty VCF ... more vertebral bodies, resulting in persistent and unbearable ... is a leading cause of VCF among elderly ... tumors, and traumatic injuries also cause VCF. Individuals ... rectify the condition. Both procedures are minimally invasive ...
(Date:9/2/2015)... 2015  The report on breast cancer therapeutics: pipeline ... drugs on the basis of the molecules which are ... inner lining of milk ducts or lobules responsible for ... tumor that can spread to other cells present in ... lobules is referred as lobular carcinoma, while the other ...
(Date:9/2/2015)... , Sept. 2, 2015 About Neuroendovascular ... used to treat an unruptured and ruptured brain ... The treatment is either known as an endovascular ... endovascular coil blocks the blood flow in an ... under general anaesthesia by an interventional neuroradiologist using ...
Breaking Medicine Technology:Global Balloon Kyphoplasty Market 2015-2019 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... Oct. 7, 2011 Akorn, Inc. (NASDAQ: ... 1, 2011, to discuss third quarter 2011 results followed by ... same day before the market opens. Subject: , Akorn, ... 1, 2011, at 10:00 a.m. Eastern TimeDomestic Callers: , ...
... 7, 2011 The Consumer Healthcare Products Association ... Assembly to adopt a new tool in the ... Meth Offender Registry Block List.  The block list ... containing pseudoephedrine (PSE) –medicines like Advil Cold and ...
Cached Medicine Technology:Consumer Group Advances Alternative to Prescription Mandate 2Consumer Group Advances Alternative to Prescription Mandate 3
(Date:9/3/2015)... ... 03, 2015 , ... For the second year in a ... list of fastest-growing private companies in America. President and Editor-in-Chief of Inc. ... have demonstrated such remarkably consistent high growth, particularly in the difficult economic environment ...
(Date:9/3/2015)... ... 03, 2015 , ... Global Vision , the world leader in the ... award-winning print and artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations ... Olympia London, booth #F33 , Be the first to get a sneak peek of ...
(Date:9/3/2015)... Philadelphia (PRWEB) , ... September ... ... global provider of high-quality patient safety and efficacy endpoint data collection, cloud ... Annual European PRO and eCOA Congress in Lisbon, Portugal, September 22-24, 2015. ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent ... Play , and Amazon and will be released on DVD early next ... is a Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed ...
(Date:9/3/2015)... ... ... types of people who have a hard time gaining weight , it seems that ... those that have a fast metabolism. In order to help those people who have a ... slowing down metabolism. , The first thing to do is to space out meals. When ...
Breaking Medicine News(10 mins):Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3
... Roya Sayadi and Joel Herskowitz. They are a wife-husband ... swallowing problems are everywhere and they can be deadly., ... in the elderly," said Sayadi, a speech-language pathologist with the ... do many things to prevent falls. But not many people ...
... The Children,s Hospital and the University of Colorado ... a center for advanced maternal fetal medicine offering state-of-the-art ... The two leading academic medical centers have individually provided ... building on already existing adult and pediatric expertise, they ...
... Doheny HealthDay Reporter , FRIDAY, July 16 (HealthDay ... concerned you,ll strike out at the company softball game? ... to a new study. So if you have a ... job or promotion in the past, take advantage. Having ...
... myeloma is one of the most common blood cancers, and ... from Uppsala University, researchers now present a conceptually new model ... was done in collaboration with Vrije Universitet Brussels and is ... PLoS ONE . Using large cohorts of myeloma patients ...
... between insect predators and their prey, chemical signals called ... the predators, the compounds are detected by their prey, ... body size or armor, that help protect the prey. ... world, their chemical identity has remained largely unknown. New ...
... up the demand for mental health care services, cash-strapped ... new Brandeis University study out this month in the ... most nations are cutting spending, a handful of countries ... mental health problems., In the U.S., public spending on ...
Cached Medicine News:Health News:Swallowing safely is no choke 2Health News:New joint program for high-risk pregnant women and their babies 2Health News:New joint program for high-risk pregnant women and their babies 3Health News:Good Luck Charms Might Just Work 2Health News:Scientists identify nature's insect repellents 2Health News:Mental health woes grow while spending declines 2
...
...
... Retriever is for arthroscopic and open soft tissue ... complicated procedural steps. It may be used ... and in conjunction with,anchors or screws (including suture ... needle tip permits the placement of a variety ...
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
Medicine Products: